In IMMUNOTARGET study, among 271 KRAS mutated patients, where immunotherapy was administered as monotherapy in advanced line, response rate was 26% with higher proportion of long responders (12-months PFS: 25.6%) as compared with other oncogenic-driven NSCLC (142). Here, KRAS is linked to non-small cell lung carcinoma.